Astellas To Develop Beta-Secretase Inhibitor For Alzheimer’s In Deal With CoMentis
This article was originally published in The Pink Sheet Daily
Executive Summary
$760 million gets Japanese pharma a Phase I compound and research into more potential disease modifying therapies for Alzheimer’s.
You may also be interested in...
Start-Up Archer Preps Alzheimer’s Drugs For Phase I
IND filed, company aims to use nilvadipine derivative against soluble amyloid.
Start-Up Archer Preps Alzheimer’s Drugs For Phase I
IND filed, company aims to use nilvadipine derivative against soluble amyloid.
Astellas Announces 32 Percent Earnings Increase For Fiscal 2007
Tokyo firm anticipates 10.4 percent drop in fiscal 2008 with Prograf patent expiry.